Gilead acquired all outstanding equity of Tubulis for $3.15bn upfront, plus up to $1.85bn in milestone payments.
The acquisition provides Gilead access to advanced ADC technologies. Credit: Melnikov Dmitriy / Shutterstock.com.
Gilead Sciences has concluded its acquisition of Tubulis, a Germany-based biotechnology company developing next-generation antibody-drug conjugates (ADCs), in a transaction valued at up to $5bn.
First announced last month, the move aims to advance Gilead’s oncology portfolio. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
